Kintara Therapeutics, Inc.
KTRA
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 79.42% | 15.11% | -36.94% | -25.22% | -12.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.78% | -36.86% | -70.88% | -36.25% | -38.64% |
| Operating Income | 28.78% | 36.86% | 70.88% | 36.25% | 38.64% |
| Income Before Tax | 30.31% | 38.39% | 70.38% | 35.55% | 38.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.31% | 38.39% | 70.38% | 35.55% | 38.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.31% | 38.39% | 70.38% | 35.55% | 38.76% |
| EBIT | 28.78% | 36.86% | 70.88% | 36.25% | 38.64% |
| EBITDA | 28.97% | 36.81% | 71.18% | 36.36% | 38.75% |
| EPS Basic | 97.86% | 97.67% | 88.77% | 46.10% | 54.42% |
| Normalized Basic EPS | 97.86% | 97.68% | 88.78% | 45.08% | 54.43% |
| EPS Diluted | 97.86% | 97.67% | 88.77% | 46.10% | 54.42% |
| Normalized Diluted EPS | 97.86% | 97.68% | 88.78% | 45.08% | 54.43% |
| Average Basic Shares Outstanding | 3,159.01% | 2,552.50% | 163.97% | 17.35% | 34.39% |
| Average Diluted Shares Outstanding | 3,159.01% | 2,552.50% | 163.97% | 17.35% | 34.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.00% | -0.62% | -2.38% | -0.55% | -0.63% |
